| PMC full text: | Sci Transl Med. Author manuscript; available in PMC 2014 Sep 19. Published in final edited form as: Sci Transl Med. 2014 Mar 19; 6(228): 228ra39. doi: 10.1126/scitranslmed.3007730 |
Table 3
V1–V2 Env IgG3 response rates (A) and magnitude (B) are associated with lower ORs and correlate with decreased risk of infection
Plasma HIV-1–specific IgG3 responses from 205 vaccinees, 41 infected vaccinees (cases), and 40 placebos at 2 weeks after the last vaccination were analyzed with clades A, B, and C V1–V2 antigens for risk of infection. (A) Case-control results from the categorical analysis (responder/nonresponder) for V1–V2 antigens. (B) Case-control results from the quantitative analysis of the magnitude of the response for V1–V2 antigens. P values <0.05 are in bold.
| A. Correlation of IgG3 response rate with risk of infection in the RV144 case-control study
| |||||
|---|---|---|---|---|---|
| Sequence description | HIV-1 Env scaffold | Univariate
| IgA-adjusted
| ||
| OR | P | OR | P | ||
| V1–V2 from RV144 vaccine boost (A244 gp120) | AE.A244 V1–V2 tags | 0.494 | 0.162 | 0.391 | 0.075 |
| V1–V2 from clade C | C.1086 V1–V2 tags | 0.564 | 0.142 | 0.511 | 0.093 |
| V1–V2 from Haynes et al. (2) | gp70 B.CaseA2 V1–V2 | 0.522 | 0.131 | 0.419 | 0.054 |
| V1–V2 with mutation (169K) | gp70 B.CaseA2 V1–V2 169K | 0.354 | 0.006 | 0.317 | 0.003 |
| B. Correlation of IgG3 magnitude with risk of infection in the RV144 case-control study
| |||||
|---|---|---|---|---|---|
| Type of Env protein/sequence information | HIV-1 Env scaffold | Univariate
| IgA-adjusted
| ||
| OR | P | OR | P | ||
| V1–V2 from RV144 vaccine boost (A244 gp120) | AE.A244 V1–V2 tags | 0.791 | 0.185 | 0.682 | 0.045 |
| V1–V2 from Haynes et al. (2) | gp70 V1–V2 CaseA2 | 0.749 | 0.088 | 0.689 | 0.034 |
| V1–V2 from clade C gp120 | gp70.C. V1–V2 | 0.753 | 0.104 | 0.703 | 0.049 |